Therapeutic tools for oral candidiasiscurrent and new antifungal drugs

  1. Guillermo Quindós Andrés 1
  2. Sandra Gil Alonso 2
  3. Cristina Marcos Arias 1
  4. Elena Sevillano Peña 1
  5. Estibaliz Mateo 1
  6. Nerea Jaureguizar Albonigamayor 3
  7. Elena Eraso Barrio 1
  1. 1 Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Dentistry, Universidad del País Vasco / Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain
  2. 2 Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Dentistry, Universidad del País Vasco / Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain; Department of Pharmacology, Faculty of Medicine and Dentistry, Universidad del País Vasco / Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain
  3. 3 Department of Pharmacology, Faculty of Medicine and Dentistry, Universidad del País Vasco / Euskal Herriko Unibertsitatea (UPV/EHU), Bilbao, Spain
Show affiliations +
Journal:
Medicina oral, patología oral y cirugía bucal. Ed. inglesa

ISSN: 1698-6946

Year of publication: 2019

Volume: 24

Issue: 2

Pages: 10

Type: Article

DOI: 10.4317/MEDORAL.22978 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Medicina oral, patología oral y cirugía bucal. Ed. inglesa

Sustainable development goals

Abstract

Candidiasis is one of the most common opportunistic oral infections that presents different acute and chronic clinical presentations with diverse diagnostic and therapeutic approaches. The present study carries out a bibliographic review on the therapeutic tools available against oral candidiasis and their usefulness in each clinical situation. Recent studies on treatment of oral candidiasis were retrieved from PubMed and Cochrane Library. Nystatin and miconazole are the most commonly used topical antifungal drugs. Both antifungal drugs are very effective but need a long time of use to eradicate the infection. The pharmacological presentations of miconazole are more comfortable for patients but this drug may interact with other drugs and this fact should be assessed before use. Other topical alternatives for oral candidiasis, such as amphotericin B or clotrimazole, are not available in many countries. Oral fluconazole is effective in treating oral candidiasis that does not respond to topical treatment. Other systemic treatment alternatives, oral or intravenous, less used are itraconazole, voriconazole or posaconazole. Available novelties include echinocandins (anidulafungin, caspofungin) and isavuconazole. Echinocandins can only be used intravenously. Isavuconazole is available for oral and intravenous use. Other hopeful alternatives are new drugs, such as ibrexafungerp, or the use of antibodies, cytokines and antimicrobial peptides. Nystatin, miconazole, and fluconazole are very effective for treating oral candidiasis. There are systemic alternatives for treating recalcitrant infections, such as the new triazoles, echinocandins, or lipidic presentations of amphotericin B.

Bibliographic References

  • Aguirre Urizar, J. (2002). Oral Candidiasis. Rev Iberoam Micol. 19. 17-21
  • Sánchez-Vargas, LO,Ortiz-López, NG,Villar, M,Moragues, MD,Aguirre, JM,Cashat-Cruz, . (2005). Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol. 22. 83-92
  • Marcos-Arias, C,Vicente, JL,Sahand, IH,Eguia, A,De-Juan, A,Madariaga, . (2009). Isolation of Candida dubliniensis in denture stomatitis. Arch Oral Biol. 54. 127
  • Manfredi, M,Polonelli, L,Aguirre-Urizar, JM,Carrozzo, M,McCullough, M. (2013). Urban legends series: oral candidosis. Oral Dis. 19. 245
  • Miranda-Cadena, K,Marcos-Arias, C,Mateo, E,Aguirre, JM,Quindós, G,Eraso, . (2018). Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. Arch Oral Biol. 95. 100
  • Ceballos, A,Quindós, G,Ceballos, . (2000). The influence of different risk behaviors in the appearance of oral candidiasis in AIDS patients. Med Oral. 5. 71-80
  • Garcia-Cuesta, C,Sarrion-Pérez, MG,Bagán, J. (2014). Current treatment of oral candidiasis: A literature review. J Clin Exp Dent. 6. 576
  • Lyu, X,Zhao, C,Yan, ZM,Hua, . (2016). Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Des Devel Ther. 10. 1161
  • Patil, S,Rao, RS,Majumdar, B,Anil, . (2015). Clinical appearance of oral Candida infection and therapeutic strategies. Front Microbiol. 6. 1391
  • López-Pintor, RM,Hernández, G,de Arriba, L,de Andrés, . (2013). Oral candidiasis in patients with renal transplants. Med Oral Patol Oral Cir Bucal. 18. 381
  • Pappas, PG,Kauffman, CA,Andes, DR,Clancy, CJ,Marr, KA,Ostrosky-Zeichner, . (2016). Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 62. 1-50
  • De-La-Torre, J,Quindós, G,Marcos-Arias, C,Marichalar-Mendia, X,Gainza, ML,Eraso, . (2018). Oral Candida colonization in patients with chronic periodontitis. Is there any relationship? Rev Iberoam Micol. 35. 134
  • Coronado-Castellote, L,Jiménez-Soriano, . (2013). Clinical and microbiological diagnosis of oral candidiasis. J Clin Exp Dent. 5. 279
  • Gotzsche, PC,Johansen, H. (2014). Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev. 9. 002033
  • Zhang, LW,Fu, JY,Hua, H,Yan, Z. (2016). Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. Oral Dis. 22. 185
  • Mukherjee, PK,Chen, H,Patton, LL,Evans, S,Lee, A,Kumwenda, . (2017). Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. AIDS. 31. 81
  • Scheibler, E,Garcia, MCR,Medina da Silva, R,Figueiredo, MA,Salum, FG,Cherubini, . (2017). Use of nystatin and chlorhexidine in oral medicine: Properties, indications and pitfalls with focus on geriatric patients. Gerodontology. 34. 291
  • Marcos-Arias, C,Eraso, E,Madariaga, L,Quindós, . (2011). In vitro activities of natural products against oral Candida isolates from denture wearers. BMC Complement Altern Med. 11. 119
  • Malakhov, A,Wen, J,Zhang, BX,Wang, H,Geng, H,Chen, X. (2016). Rechargeable anticandidal denture material with sustained release in saliva. Oral Diseases. 22. 391
  • Reis, PC,Roque, LV,Baptista, M,Rijo, . (2016). Innovative formulation of nystatin particulate systems in toothpaste for candidiasis treatment. Pharm Dev Technol. 21. 282
  • Sardi, JC,Gullo, FP,Freires, IA,Pitangui, NS,Segalla, MP,Fusco-Almeida, A. (2016). Synthesis, antifungal activity of caffeic acid derivative esters, and their synergism with fluconazole and nystatin against Candida spp. Diagn Microbiol Infect Dis. 86. 387
  • Ai, R,Wei, J,Ma, D,Jiang, L,Dan, H,Zhou, . (2017). A meta-analysis of randomized trials assessing the effects of probiotic preparations on oral candidiasis in the elderly. Arch Oral Biol. 83. 187
  • Pedraza-Sánchez, S,Méndez-León, JI,Gonzalez, Y,Ventura-Ayala, ML,Herrera, MT,Lezana-Fernández, J. (2018). Oral administration of human polyvalent IgG by mouthwash as an adjunctive treatment of chronic oral candidiasis. Front Immunol. 9. 2956
  • Schneider, J,Mateo, E,Marcos-Arias, C,Eiró, N,Vizoso, F,Pérez-Fernández, . (2018). Antifungal activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) against Candida albicans and other medically relevant species of Candida. Front Microbiol. 9. 2818
  • Wiederhold, N. (2018). The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 51. 333
  • Hamill, R. (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 73. 919
  • Gil-Alonso, S,Jauregizar, N,Cantón, E,Eraso, E,Quindós, . (2015). In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies. Antimicrob Agents Chemother. 59. 3615
  • Castelli, MV,Derita, MG,López, S. (2017). Novel antifungal agents: a patent review (2013 - present). Expert Opin Ther Pat. 27. 415
  • Roque, L,Alopaeus, J,Reis, C,Rijo, P,Molpeceres, J,Hagesaether, . (2018). Mucoadhesive assessment of different antifungal nanoformulations. Bioinspir Biomim. 13. 055001
  • Iqbal, Z,Zafar, M. (2016). Role of antifungal medicaments added to tissue conditioners: A systematic review. J Prosthodont Res. 60. 231
  • Voltan, AR,Quindós, G,Alarcón, KP,Fusco-Almeida, AM,Mendes-Giannini, MJ,Chorilli, . (2016). Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?. Int J Nanomedicine. 11. 3715
  • Vazquez, JA,Sobel, J. (2012). Miconazole mucoadhesive tablets: a novel delivery system. Clin Infect Dis. 54. 1480
  • Hellfritzsch, M,Pottegård, A,Pedersen, AJ,Burghle, A,Mouaanaki, F,Hallas, . (2017). Topical antimycotics for oral candidiasis in warfarin users. Basic Clin Pharmacol Toxicol. 120. 368
  • Oude Lashof, AM,De Bock, R,Herbrecht, R,de Pauw, BE,Krcmery, V,Aoun, . (2004). An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur J Cancer. 40. 1314
  • De-la-Torre, J,Ortiz-Samperio, ME,Marcos-Arias, C,Marichalar-Mendia, X,Eraso, E,Echebarria-Goicouria, M. (2017). In vitro antifungal susceptibility of oral Candida isolates from patients suffering from caries and chronic periodontitis. Mycopathologia. 182. 471
  • Carrillo-Muñoz, AJ,Quindós, G,Ruesga, M,Alonso, R,del Valle, O,Hernández-Molina, J. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother. 55. 317
  • Azanza Perea, JR,Sádaba Díaz de Rada, . (2018). Pharmacological profile of isavuconazole. Rev Iberoam Micol. 35. 186-191
  • Quindós, G,Villar-Vidal, M,Eraso, . (2009). Actividad de la micafungina contra las biopelículas fúngicas. Rev Iberoam Micol. 26. 49-55
  • Gil-Alonso, S,Jauregizar, N,Eraso, E,Quindós, . (2016). Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades. Diagn Microbiol Infect Dis. 86. 172
  • Gil-Alonso, S,Jauregizar, N,Eraso, E,Quindós, . (2015). Postantifungal effect of micafungin against the species complexes of Candida albicans and Candida parapsilosis. PLoS One. 10. 0132730
Data source: Dialnet